Today: 18 May 2026
POET Gets $400M Infusion But Shares Drop
18 May 2026
2 mins read

POET Gets $400M Infusion But Shares Drop

New York, May 18, 2026, 12:08 EDT

  • POET locked in a US$400 million investment, selling common shares and warrants to one institutional investor.
  • Nasdaq-listed shares dropped 14.2% to $13.70 in recent trading, after starting the day higher and reaching $18.17 earlier.
  • POET got the cash days after booking a Lumilens order and reporting a first-quarter loss, adding fuel to the talk around POET’s push on AI-optics.

POET Technologies Inc. stock dropped 14.2% to $13.70 in midday trading Monday on Nasdaq. Volume was about 47.9 million shares. This came as the Canadian photonics maker said it closed a US$400 million investment to help expand in AI data-center hardware.

POET is getting a bigger cash cushion from the financing as it pushes past development and looks to ramp up manufacturing. But investors are looking at the new equity and warrants, since issuing more shares could dilute current holders if those shares hit the market.

POET said it sold 19,047,620 common shares and the same number of warrants in a registered direct offering. The shares went to MMCAP International Inc. SPC. No placement agent took part, according to the company.

The shares and warrants priced at US$21 apiece, coming in higher than POET’s Nasdaq close of US$20.57 on May 14. The warrants have a US$26.25 exercise price and run for three years.

POET shares had a choppy session. The stock started at $17.00, jumped to $18.17, then slid to $13.66, market data shows. The company’s TSX Venture shares didn’t trade Monday as TMX exchanges were shut for Victoria Day. Trading is set to resume Tuesday.

POET said it plans to use the cash for manufacturing infrastructure, deals, R&D, its light-source unit, operations and working capital. CEO Suresh Venkatesan said the company is “expanding our capacity by roughly ten-fold,” mentioning Lumilens and what he called other “high-volume opportunities.” GlobeNewswire

POET’s new funding comes after its first-quarter numbers last week. The company reported revenue of $503,389, an increase from $166,760 last year. Net loss came in at $12.3 million, or 8 cents per share. Non-recurring engineering revenue is from single customer development projects, not ongoing product sales.

Lumilens is the main story. POET said Lumilens put in a $50 million initial order for EOI-based engines, the first step in a deal that could see more than $500 million in total orders over five years. The EOI, or Electrical-Optical Interposer, platform is built to combine electronics and photonics at the wafer level, using light to move data.

Lumilens CEO Ankur Singla said “GPU interconnects” are turning into the main bottleneck for scaling AI. That’s driving investors to optical-networking stocks. POET says its gear targets 800G and 1.6T optical modules, along with near-package and co-packaged optics used in AI data centers. POET Technologies

Marvell Semiconductor in late April canceled all of POET’s purchase orders from Celestial AI, after Marvell acquired Celestial, POET said. Marvell cited alleged confidentiality problems for the move. That puts more weight on POET’s Lumilens order and its work with Lite-On and Lessengers as proof the business isn’t pinned on a single customer.

Risks for POET remain. The new warrants could mean more shares in the future. Lumilens revenue depends on how development, qualification and ramp-up go. Quarterly sales are still small compared with the opportunity described. If there are delays in qualification, if future orders don’t materialize, or if investors see dilution as a problem, the stock could keep facing pressure.

Management is shifting at POET. The company named Sandeep Kumar as chief operating officer. Chief Financial Officer Thomas Mika has told the board he plans to retire this year, after a decade in the post.

Traders this week will be watching if U.S. shares stick near the $21 financing level or keep dropping toward Monday’s low. Canadians get their first shot to react in regular TSX Venture trading when it opens Tuesday.

Latest articles

POET Gets $400M Infusion But Shares Drop

POET Gets $400M Infusion But Shares Drop

18 May 2026
POET Technologies closed a US$400 million direct investment with MMCAP International, issuing 19 million shares and warrants at $21 each. Shares fell 14.2% to $13.70 in heavy Nasdaq trading after opening higher. The funding follows a $50 million Lumilens order and a first-quarter net loss of $12.3 million. TSX Venture shares did not trade due to a Canadian holiday.
Why Plug Power Stock Is Falling Today After Its Hydrogen Rally

Why Plug Power Stock Is Falling Today After Its Hydrogen Rally

18 May 2026
Plug Power shares dropped 9.8% to $3.41 in late-morning trading Monday, erasing part of last week’s post-earnings rally. The company reported first-quarter revenue of $163.5 million and improved margins, but posted a net loss of $245.3 million. Investors remain concerned about cash burn and future dilution. Other hydrogen stocks also fell sharply.
Ford’s Energy Bump Cools Off Despite EDF Tie-Up; EV Worries Still Linger

Ford’s Energy Bump Cools Off Despite EDF Tie-Up; EV Worries Still Linger

18 May 2026
Ford shares fell 1.2% to $13.24 by midday Monday after announcing a battery-storage deal with EDF and a new Europe product plan. The EDF agreement could bring up to 20 GWh of storage orders over five years, but deliveries start in 2028. Ford also plans to launch seven new models in Europe by 2029.
Nasdaq 100 Falls Below 29,000 as Wall Street Eyes Market Moves

Nasdaq 100 Falls Below 29,000 as Wall Street Eyes Market Moves

18 May 2026
The Nasdaq-100 dropped below 29,000 on Monday, closing at 28,880.80, down 0.84%. Technical analysts flagged 29,000 as key support, with chip stocks and AI shares central to the recent rally. The 10-year Treasury yield eased to 4.573%, while Brent crude fell nearly 2%. Nvidia’s earnings on Wednesday are now in focus as traders gauge the market’s next move.

Popular

GeoVax moves higher before the bell as traders watch for Mpox vaccine news

GeoVax moves higher before the bell as traders watch for Mpox vaccine news

18 May 2026
GeoVax Labs shares more than doubled in U.S. pre-market trading Monday, quoted at $2.34–$2.61 after closing Friday at $1.23. The surge followed last week’s first-quarter update and news of a planned Phase 3 trial for its GEO-MVA vaccine, not a new clinical result. GeoVax reported $1.27 million in cash at March 31 and warned it may need new funding by June 2026.
Why Plug Power Stock Is Falling Today After Its Hydrogen Rally
Previous Story

Why Plug Power Stock Is Falling Today After Its Hydrogen Rally

Go toTop